IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2435
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$67M
Sergio Traversa
Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$RLMD RELMADA THERAPEUTICS, INC. | 47 | 18 | 19 | 87 | - | - | -625.9% | -398.2% | - | - | - | - | 0.0% | 57.0x | $67M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
RELMADA THERAPEUTICS, INC. (RLMD) receives a "Reduce" rating with a composite score of 47.3/100. It ranks #2435 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for RLMD.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 18 | 2 | +16ALPHA |
| MOMENTUM | 87 | 93 | -6DRAG |
| VALUATION | 19 | 9 | +10ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 33 | 20 | +13ALPHA |
| SHORT INT | 73 | 84 | -11DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -625.9% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate RELMADA THERAPEUTICS, INC. (RLMD) as a Reduce with a composite score of 47.3/100 at a current price of $4.26. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
RELMADA THERAPEUTICS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.3/100 places it at rank #2435 in our full universe.
No Moat
High
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
RELMADA THERAPEUTICS, INC. represents a reduce based on multi-factor quantitative performance.
RELMADA THERAPEUTICS, INC. receives a Reduce rating from our analysis, with a composite score of 47.3/100 and 2 out of 5 stars, ranking #2435 out of 7,333 stocks. RLMD's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
RELMADA THERAPEUTICS, INC. registers a weak quality score of just 18/100, indicating significant profitability challenges. The company reports a return on equity of -625.9% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
RLMD registers a value score of just 19/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 32.00x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
RELMADA THERAPEUTICS, INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -398.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
RLMD shows strong momentum characteristics with a score of 87/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 0.84 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
RLMD's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.84 and a debt-to-equity ratio of 57.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
RLMD carries a short interest score of 73/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 57.00x), micro-cap liquidity risk. At $67M market cap (micro-cap), RELMADA THERAPEUTICS, INC. offers reasonable institutional liquidity.
RELMADA THERAPEUTICS, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2435 of 7,333 overall (67th percentile). Key comparisons include ROE of -625.9% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RLMD currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (18) would have the largest impact on the composite score.
ROE 32841% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 27043% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous sy
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares jumped 170.2% to $4.62. Omega Therapeutics, Inc. (NASDAQ: OMGA) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company. Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 65.8% to $0.2920 after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol. Jeffs' Brands Ltd(NASDAQ: JFBR) gained 40% to $4.41 after surging 25% on Wednesday. Jeffs' Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology. Mobix Labs, Inc. (NASDAQ: MOBX) gained 33.3% to $4.00. Mobix Labs was awarded 15-month contract to supply EMI filtered connectors as part of US Army's M-1 Abrams Tank Program. ATIF Holdings Limited (NASDAQ: ATIF) jumped 30.6% to $1.32. Adicet Bio, Inc. (NASDAQ: ACET) surged 26.1% to $2.22. Adicet Bio issued corporate updates and highlighted upcoming priorities for its pipeline programs in 2024. Smart for Life, Inc. (NASDAQ:
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million. The company reported a Q2 EPS loss of $(1.54), missing the consensus of $(1.24). Sales from Auvelity, a prescription oral medicine used to treat adults with major depressive disorder (MDD), reached $27.6 million, up 76% sequentially. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022. Approximately 53,000 prescriptions were reported for Auvelity in Q2, up 72% sequentially. Sunosi's revenue was $19.1 million, consisting of $18.4 million in net product sales and $0.7 million in royalty revenue ...Full story available on Benzinga.com
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls